# EDGAR Filing Document

**Accession Number:** 0001593773
**File Stem:** 0001477932-26-002852
**Filing Date:** 2026-5
**Character Count:** 84416
**Document Hash:** 00363262134c51c9b7f04a3ec8b6501a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-002852.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001477932-26-002852

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 48

**CONFORMED PERIOD OF REPORT**: 20250831

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMJ Global Technology
- **CENTRAL INDEX KEY:** 0001593773
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING SERVICES [7371]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 331230169
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-194055
- **FILM NUMBER:** 26955416

**BUSINESS ADDRESS:**
- **STREET 1:** 2470 E FLAMINGO RD
- **STREET 2:** SUITE A
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89121
- **BUSINESS PHONE:** 213-709-4296

**MAIL ADDRESS:**
- **STREET 1:** 2470 E FLAMINGO RD
- **STREET 2:** SUITE A
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KANGE CORP
- **DATE OF NAME CHANGE:** 20131209

?xml version='1.0' encoding='ASCII'? amj_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **<u>August 31, 2025</u>**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ____________ to ____________

Commission File Number: **<u>333-194055</u>**

---

| |
|:---|
| **AMJ Global Technology** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **33-1230169** |
| (State or other jurisdiction<br>of incorporation) | (IRS Employer<br>Identification Number) |

---

**2470 E Flamingo Rd., Suite A**

**<u>Las Vegas, NV 89121</u>**

(Address of principal executive offices)

**<u>(213) 709-4296</u>**

(Registrant's telephone number, including area code)

**______________________________________________**

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of May 4, 2026, the Company had 111,922,857 shares of common stock outstanding.

**AMJ Global Technology**

**INDEX**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| **[PART I. FINANCIAL INFORMATION](#p1)** | **[PART I. FINANCIAL INFORMATION](#p1)** |  |
| [Item 1.](#i1) | [Financial Statements](#i1) | 3 |
| [Item 2.](#i2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2) | 4 |
| [Item 3.](#i3) | [Quantitative and Qualitative Disclosures about Market Risks](#i3) | 9 |
| [Item 4.](#i4) | [Controls and Procedures](#i4) | 9 |
| **[PART II. OTHER INFORMATION](#p2)** | **[PART II. OTHER INFORMATION](#p2)** |  |
| [Item 1.](#ii1) | [Legal Proceedings](#ii1) | 10 |
| [Item 1A.](#ii1a) | [Risk Factors](#ii1a) | 10 |
| [Item 2.](#ii2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#ii2) | 10 |
| [Item 3.](#ii3) | [Defaults Upon Senior Securities](#ii3) | 10 |
| [Item 4.](#ii4) | [Mine Safety Disclosures](#ii4) | 10 |
| [Item 5.](#ii5) | [Other Information](#ii5) | 10 |
| [Item 6.](#ii6) | [Exhibits](#ii6) | 11 |
| [SIGNATURES](#sign) | [SIGNATURES](#sign) | 12 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#toc)* |

---

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**AMJ Global Technology**

**Table of Contents**

---

| | |
|:---|:---|
|  | **Page** |
| [Condensed Balance Sheets at August 31, 2025, and November 30, 2024 (unaudited)](#bs) | F-1 |
| [Condensed Statements of Operations for the Three and Nine months ended August 31, 2025, and August 31, 2024 (unaudited)](#op) | F-2 |
| [Condensed Statements of Changes in Stockholders' Deficit for the Three and Nine months ended August 31, 2025, and August 31, 2024 (unaudited)](#eq) | F-3 |
| [Condensed Statements of Cash Flows for the Nine months ended August 31, 2025, and August 31, 2024 (unaudited)](#cf) | F-4 |
| [Notes to Unaudited Condensed Financial Statements](#n) | F-5 |

---

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#tocf)* |

---

**AMJ Global Technology**

**Condensed Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **August 31,**<br>**2025** | **November 30,**<br>**2024** |
| **ASSETS** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash | $110 | $226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable - related party | 664 | 39 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 280 | 5280 |
| Total Current Assets | 1054 | 5545 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medicare contracts asset-related party |  | 337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Software and technology assets, net | - | 3371 |
| **TOTAL ASSETS** | $1054 | $9253 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $15645 | $4762 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued management fees - related party | 270000 | 180000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related party | 39114 | 16166 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related party-Medicare contracts asset acquisition | 914029 | - |
| Total Current Liabilities | 1238788 | 200928 |
| Total Liabilities | 1238788 | 200928 |
| **Stockholders' Deficit** |  |  |
| Common stock, $0.001 par value, 750,000,000 shares authorized, 106,472,857 and 107,782,190 shares issued and outstanding, respectively | 106473 | 107782 |
| Additional paid-in capital | 200755 | 176817 |
| Accumulated deficit | (1544962) | (476274) |
| Total Stockholders' Deficit | (1237734) | (191675) |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $1054 | $9253 |

---

 *The accompanying notes are an integral part of these unaudited condensed financial statements.*

---

| |
|:---|
| F-1 |
| *[**Table of Contents**](#tocf)* |

---

**AMJ Global Technology**

**Condensed Statements of Operations**

 **(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 31,** | **August 31,** | **August 31,** | **August 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues - related party | $232 | $8 | $674 | $8 |
| Operating Expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 1602 | 7120 | 5027 | 10120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 4891 | 7949 | 39968 | 37622 |
| &nbsp;&nbsp;&nbsp;&nbsp;Management compensation | 30000 | 35764 | 110000 | 97859 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 36493 | 50833 | 154995 | 145601 |
| Operating loss | (36261) | (50825) | (154321) | (145593) |
| Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (11781) |  | (28135) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement of debt - related party |  |  |  | 98109 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment acquisition | (886232) | - | (886232) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expenses) | (898013) | - | (914367) | 98109 |
| Net loss before income taxes | (934274) | (50825) | (1068688) | (47484) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes |  |  |  |  |
| Net Loss | $(934274) | $(50825) | $(1068688) | $(47484) |
| Basic and diluted income (loss) per common share | $(0.01) | $(0.00) | $(0.01) | $(0.00) |
| Basic and diluted weighted average common shares outstanding | 106472857 | 104843639 | 107234570 | 103823750 |

---

*The accompanying notes are an integral part of these unaudited condensed financial statements.*

---

| |
|:---|
| F-2 |
| *[**Table of Contents**](#tocf)* |

---

**AMJ Global Technology**

**Condensed Statements of Changes in Stockholders' Deficit**

**(Unaudited)**

 **For the Three and Nine Months Ended August 31, 2025**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares**  | **Amount**  | **Additional** <br>**Paid in** <br>**Capital**  | <br>**Accumulated** <br>**Deficit**  | **Total**<br>**Stockholders'**<br>**Deficit**  |
| Balance - November 30, 2024 | 107782190 | $107782 | $176817 | $(476274) | $(191675) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued in cash | 3000 | 3 | 2997 |  | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (55362) | (55362) |
| Balance - February 28, 2025 | 107785190 | 107785 | 179814 | (531636) | (244037) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued in cash | 3000 | 3 | 2997 |  | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock cancelled for termination software and technology asset | (1333333) | (1333) | (2038) |  | (3371) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services - related party | 20000 | 20 | 19980 |  | 20000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock cancelled by one stockholder | (2000) | (2) | 2 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (79052) | (79052) |
| Balance - May 31, 2025 | 106472857 | 106473 | 200755 | (610688) | (303460) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (934274) | (934274) |
| Balance - August 31, 2025 | 106472857 | $106473 | $200755 | $(1544962) | $(1237734) |

---

**For the Three and Nine Months Ended August 31, 2024**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br> **Paid in**<br> **Capital** |<br>**Accumulated**<br> **Deficit** | **Total**<br>**Stockholders'**<br> **Deficit** |
| Balance - November 30, 2023 | 103033323 | $103033 | $169469 | $(390577) | $(118075) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (49674) | (49674) |
| Balance - February 29, 2024 | 103033323 | 103033 | 169469 | (440251) | (167749) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for settlement of debt- related party | 202200 | 203 | 327 |  | 530 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for compensation - related party | 400000 | 400 | 648 |  | 1048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services - related party | 400000 | 400 | 648 |  | 1048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income for the period | - | - | - | 53015 | 53015 |
| Balance - May 31, 2024 | 104035523 | 104036 | 171092 | (387236) | (112108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for software and development acquisition | 1333333 | 1333 | 2038 |  | 3371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for revenue sharing agreement - related party | 133334 | 133 | 204 |  | 337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for compensation - related party | 2250000 | 2250 | 3437 |  | 5687 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services - related party | 30000 | 30 | 46 |  | 76 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (50825) | (50825) |
| Balance - August 31, 2024 | 107782190 | 107782 | 176817 | (438061) | (153462) |

---

*The accompanying notes are an integral part of these unaudited condensed financial statements.*

---

| |
|:---|
| F-3 |
| *[**Table of Contents**](#tocf)* |

---

**AMJ Global Technology**

**Condensed Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 31,** | **August 31,** |
|  | **2025** | **2024** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(1068688) | $(47484) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Imputed interest | 28134 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment acquisition | 886232 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation for services - related party | 20000 | 1124 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management stock-based compensation |  | 6735 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement of debt - related party |  | (98109) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable-related party | (625) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 5000 | 5526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 6383 | 2643 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses - related party | 4500 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued management fee - related party | 90000 | 90000 |
| Net cash used in operating activities | (29064) | (39573) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from advances from related party | 25274 | 39802 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of advances to related party | (2326) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contribution from common stock issued | 6000 | - |
| Net cash provided by financing activities | 28948 | 39802 |
| Net change in cash for the period | (116) | 229 |
| Cash at beginning of period | 226 | - |
| Cash at end of period | $110 | $229 |
| **SUPPLEMENTAL CASH FLOW INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for settlement of debt - related party | $- | $530 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for compensation - related party | $- | $6735 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services - related party | $20000 | $1124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cancellation software and technology asset, net | $3371 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cancellation common stock | $2 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for software and development acquisition | $- | $3371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for revenue sharing agreement - related party | $- | $337 |

---

*The accompanying notes are an integral part of these unaudited condensed financial statements.*

---

| |
|:---|
| F-4 |
| *[**Table of Contents**](#tocf)* |

---

**AMJ Global Technology**

**Notes to Unaudited Condensed Financial Statements**

**August 31, 2025**

**NOTE 1 – ORGANIZATION, BUSINESS AND LIQUIDITY**

***Business***

AMJ Global Technology (the "Company") was incorporated under the laws of the State of Nevada on August 16, 2013, originally incorporated as Kange Corp. Effective April 22, 2023, the Company filed with the State of Nevada a Certificate of Amendment to its Articles of Incorporation, changing the name of the Company to AMJ Global Technology. We are a start-up company developing mobile software products, starting in Estonia and Europe, which is our initial intended market. During year 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments. We retained an advisor having substantial experience in the technology sector, and two former professional athletes to advise us regarding sports health issues and treatments. We intend to provide services to formulate a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer'. The Company is currently evaluating operations in the wholistic health industry, revenue sharing generated from Medicare enrollees, life and annuity insurance sales.

On April 26, 2023, the Company entered into an assignment agreement with AMJ Global Entertainment, LLC, a Nevada limited liability company controlled by the Company's CEO and director., pursuant to which AMJ Global Entertainment, LLC assigned to the Company 25% of the ownership rights to AMJ Global Entertainment's intellectual property in connection with the "Blabeey" platform, including software, code and trade secrets at zero cost.

***Basis of Presentation***

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the financial statements are condensed and do not include all of the information and footnotes required by GAAP for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the results of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report on Form 10-K, for the year ended November 30, 2024, as filed with the SEC on March 3, 2025.

***Use of Estimates***

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

***Accounts Receivable***

Accounts receivables are recorded in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 310, "*Receivables."* Accounts receivables are recorded at the invoiced amount or agreement and do not bear interest. The Company does not currently have any amount recorded as an allowance for doubtful accounts. Based on the management's estimate and based on all accounts being current, the Company has not deemed it necessary to reserve for doubtful accounts at this time.

---

| |
|:---|
| F-5 |
| *[**Table of Contents**](#tocf)* |

---

***Revenue Recognition***

The Company recognizes revenue from its contracts with customers in accordance with *ASC 606 – Revenue from Contracts with Customers.* The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

Revenue related to contracts with customers is evaluated utilizing the following steps:

(i) Identify the contract, or contracts, with a customer;

(ii) Identify the performance obligations in the contract;

(iii) Determine the transaction price;

(iv) Allocate the transaction price to the performance obligations in the contract;

(v) Recognize revenue when the Company satisfies a performance obligation.

The Company has two Medicare revenue sharing contracts with a related party that requires 5% and 25% net revenue generated from two Medicare contracts (Note 3). The Company recognizes the monthly revenue with thirty (30) days terms of payment.

<u>Financial Instruments and Fair Value Measurements</u>

As defined in ASC 820" Fair Value Measurements," fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement), other inputs that are directly or indirectly observable in the market place (level 2 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

<u>Fair Value of Financial Instruments</u>

The *Financial Instruments* ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows ASC subtopic 820-10, *Fair Value Measurements and Disclosures* ("ASC 820-10") and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.

The following table summarizes fair value measurements by level as of August 31, 2025 and November 30, 2024, measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **August 31, 2025** | **(Level 1)** | **(Level 2)** | **(Level 3)** | **Total** |
| **Assets:** |  |  |  |  |
| Medicare contracts asset-related party | $- | $- | $- | $- |
| **<u>Liabilities</u>** |  |  |  |  |
|  | $- | $- | $- | $- |
| **November 30, 2024** | **(Level 1)** | **(Level 2)** | **(Level 3)** | **Total** |
| **Assets:** |  |  |  |  |
| Medicare contracts asset-related party | $- | $- | $337 | $337 |
| **<u>Liabilities</u>** |  |  |  |  |
|  | $- | $- | $- | $- |

---

---

| |
|:---|
| F-6 |
| *[**Table of Contents**](#tocf)* |

---

***Equity Investment – Related Party***

Equity investments with readily determinable fair values are measured at fair value. Equity investments without readily determinable fair values are measured using the equity method or measured at cost with adjustments for observable changes in price or impairments (referred to as the measurement alternative). We perform a qualitative assessment on a periodic basis and recognize an impairment if there are sufficient indicators that the fair value of the investment is less than carrying value. Changes in value are recorded in other income (expenses). The Company recognized the net loss (income) generated from equity investment based on investee net loss (income) by using equity method accounting.

The 25% Equity Investment in AMJ Global Entertainment, LLC ("AMJ") acquired on April 26, 2023, a related party controlled by the Company's CEO and director, is accounted for under the equity method as the investment provides us with the ability to exercise significant influence over operating and financial policies of AMJ. On acquisition of AMJ, the investment had no value and as of August 31, 2025, AMJ has sustained losses. The carrying amount of this investment as of August 31, 2025, and November 30, 2024, is $0.

***Intangible & Contract Assets***.

Intangible assets with finite lives are initially recorded at cost and amortized on a straight-line basis over the estimated economic useful lives of the respective assets. Acquired intangible assets from business combinations and asset acquisitions are recognized and measured at fair value at the time of acquisition. Those assets represent assets with finite lives and are further amortized on a straight-line basis over the estimated economic useful lives of the respective assets.

The capitalized costs of contract assets are amortized over the expected benefit period (which may include renewal periods) and must be assessed for impairment if the carrying amount exceeds recoverable future revenue.

On May 7, 2025, the Company entered into an unwinding agreement with the owner of software and technology assets to terminate the agreement dated August 25, 2024 (Note 4).

The Medicare contract assets of 5% and 25% are indefinite contracts, therefore the Company determined the fair value of the contracts and recognized the impairment acquisition of $337 and $883,895, respectively based on (i) the Target not issuing stock in favor of the Company, (ii) the Target not providing financial statements, (iii) lack of generated revenue against the forecast revenue provided at acquisition date, (iv) unfavorable outcome.

***Net Loss Per Share of Common Stock***

The Company has adopted ASC Topic 260, "*Earnings per Share"* which requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. There are no dilutive or potentially dilutive securities outstanding during the periods presented.

***Cash and Cash Equivalents***

For purposes of balance sheet presentation and reporting of cash flows, the Company considers all unrestricted demand deposits, money market funds and highly liquid debt instruments with an original maturity of less than 90 days to be cash and cash equivalents. The Company did not have any cash equivalents at August 31, 2025, and November 30, 2024. The Company had cash of $110 and $226 at August 31, 2025, and November 30, 2024, respectively.

---

| |
|:---|
| F-7 |
| *[**Table of Contents**](#tocf)* |

---

***Recent Accounting Pronouncements***

The Company has implemented all the new pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial statements or results of operations.

***Income Taxes***

Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes. A full valuation allowance for deferred tax assets has been provided because the Company believes it is not more likely than not that the deferred tax asset will be realized. Realization of deferred tax assets is dependent on the Company generating sufficient taxable income in future periods.

The Company periodically evaluates its tax positions to determine whether it is more likely than not that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. As of August 31, 2025, and November 30, 2024, the Company has not established a liability for uncertain tax positions.

***Reclassification***

Certain amounts from prior periods have been reclassified to conform to the current period presentation.

**NOTE 2 – GOING CONCERN AND LIQUIDITY CONSIDERATION**

**Going Concern**

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company used cash in operating activities of $29,064 for the nine months ended August 31, 2025. The Company had an accumulated deficit of $1,544,962 on August 31, 2025. These factors, among others, raise substantial doubts about the ability of the Company to continue as a going concern for a period of at least one year from date of issuance of the financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing, shareholder loans and to commence profitable operations in the future and repay its liabilities (due to related party-99% of total liabilities) arising from normal business operations as they become due. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for future periods. We have no assurance that future financing will be available to us on acceptable terms. Equity financing could result in additional dilation to existing shareholders.

The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

---

| |
|:---|
| F-8 |
| *[**Table of Contents**](#tocf)* |

---

**NOTE 3 – MEDICARE CONTRCT ASSET - RELATED PARTY**

***Acquisition 5%:***

On July 13, 2024, the Company entered into a Revenue Sharing agreement with a company controlled by a Target, a related party for acquisition of 5% of Target's issued and outstanding stock, pursuant to which the Company will receive 5% of net revenue generated from two contracts with (i) ESS in connection with Medicare enrollees, and (ii) The Agency of North Georgia in connection with Medicare, life and annuity insurance sales in exchange for 133,334 shares of common stock for a unlimited period. The Company issued 133,334 shares of common stock issued on July 10, 2024, valued at $337. As of August 31, 2025, the Company determined the fair value of 5% Medicare contract asset and recognized impairment acquisition of $337 due to (i) Target not issuing stock in favor of the Company, (ii) Target not providing financial statements and (iii) lack of generated revenue against the forecast revenue provided at acquisition date (iv) unfavorable outcome. The carrying amount of this investment as of August 31, 2025, and November 30, 2024, is $0 and $337, respectively.

Pursuant to above disclosure, the Company reclassified 5% equity investment to other assets named "Medicare Contract Asset- related party" and unpaid revenue sharing under "Accounts Receivable-related party".

During the nine months ended August 31, 2025, the Company recognized $143 contract asset revenue generated from Target's contracts.

As of August 31, 2025, the Company had Medicare contract asset as follows:

---

| | |
|:---|:---|
| Acquisition amount  | $337 |
| Adjustments: |  |
| Medicare contract income net of distributions received | 133 |
|  | 470 |
| Impairment acquisition  | (337) |
| Reclassified unpaid income as account receivable  | (133) |
|  | $- |

---

On January 15, 2026, the Company collected accounts receivable of $133.

***Acquisition 25%:***

On January 24, 2025, the Company entered into a binding Letter of Intent (LOI) with AMJ Global Entertainment, LLC ("Seller"), controlled by the Company's CEO and director for acquisition 100% of AMJ Global Entertainment's 25% of target's equity stake in a company controlled by a Target, a related party for amount of $1,000,000 in cash with payment term of two years with an extension of four months to pay the unpaid balance. Should the Company not be able to pay the outstanding balance at the end of twenty- eight (28) months, the Seller has agreed to take any outstanding unpaid balance in restricted stock of the Company at the price at of the stock at the time of signing agreement, which would be $1.00 per share. The Company recognized discount on non-interest-bearing loan issued by using Applicable Federal Rate (AFR) of 5.20% of $114,105 on acquisition date and recognized the asset at fair value.

In March 2026, the Company entered into a cancellation / unwinding agreement with Seller to cancel and terminate the original agreement and resolve any and all claims, obligations and liabilities arising there from with effective date of August 31, 2025, due to (i) not issuance stock in favor of the Company, (ii) not providing financial statements and (iii) lack of generated revenue against the forecast revenue provided at acquisition date. The Company acknowledges that agreement was determined not to have enforceable rights and obligations and hence the amounts related to the contract asset and corresponding loan payable, therefore the amounts related to the Medicare contract asset and corresponding loan payable would be rescinded and reversed on execution date of agreement (March 2026).

Pursuant to above disclosure, the Company reclassified 25% equity investment to other assets named "Medicare Contract Asset- related party" and unpaid revenue sharing under "Accounts Receivable-related party".

---

| |
|:---|
| F-9 |
| *[**Table of Contents**](#tocf)* |

---

As of August 31, 2025, the Company revalued the 25% Medicare contract asset and recognized impairment acquisition of $885,895 due to above reasons and unfavorable outcome raised. The carrying amount of this investment as of August 31, 2025, is $0.

During the nine months ended August 31, 2025, the Company recognized $531 contract asset revenue generated from Target's contracts

As of August 31, 2025, the Company had equity investments as follows:

---

| | |
|:---|:---|
| Acquisition amount  | $1000000 |
| Adjustments: |  |
| Discount on non-interest - bearing loan for acquisition  | (114105) |
| Medicare contract income net of distributions received | 531 |
|  | 886426 |
| Impairment acquisition  | (885895) |
| Reclassified unpaid income as account receivable | (531) |
|  | $- |

---

On January 15, 2026, the Company collected accounts receivable of $531.

**NOTE 4 – SOFTWARE AND TECHNOLOGY ASSET**

As of August 31, 2025, and November 30, 2024, the Company had software and technology assets as follows:

---

| | | |
|:---|:---|:---|
|  | **August 31,**<br>**2025** | **November 30,**<br>**2024** |
| Software and technology assets | $3371 | $3371 |
| Accumulated amortization | (348) | - |
|  | 3023 | 3371 |
| Terminated agreement | (3371) |  |
| Reversed accumulated amortization | 348 | - |
|  | $- | $3371 |

---

On August 25, 2024, the Company entered into a Software Purchase and Development agreement, pursuant to which the Company acquired an 8% interest in database software and related technology assets in exchange for 1,333,333 shares of common stock. The Company issued 1,333,333 shares of common stock on August 26, 2024, valued at $3,371. This asset represent asset with finite lives 5 years and are further amortized on a straight-line basis over the estimated economic useful lives of the respective assets. During the nine months ended August 31, 2025, the Company recognized and reversed amortization expenses of $348. The Company did not earn revenue for nine months ended August 31, 2025.

On May 7, 2025, the Company entered into an unwinding agreement with the owner of software and technology assets to terminate the agreement dated August 25, 2024. Upon the termination of the original agreement, neither party shall have any further obligations or liabilities under the original agreement. The Company received irrevocable cancellation 1,333,333 shares of common stock on May 7, 2025, which were transferred back to the Company as treasury stock and was cancelled and reversed the accumulated amortization expenses of $348.

**NOTE 5 – RELATED PARTY TRANSACTIONS**

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such a time that the Company can support its operations or attain adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are non-interest bearing, considered temporary in nature, and have not been formalized by a promissory note.

---

| |
|:---|
| F-10 |
| *[**Table of Contents**](#tocf)* |

---

During the nine months ended August 31, 2025, and 2024, AMJ Global Entertainment LLC, a related party controlled by the Company's CEO and director advanced to the Company an amount of $22,773 and $39,302 by paying for operating expenses on behalf of the Company, $2,501 and $500 in cash and the Company repaid advances to a related party of $2,326 and $0, respectively.

During the nine months ended August 31, 2025, and 2024, the Company recognized management compensation of $90,000 and $90,000, respectively. As of August 31, 2025, and November 30, 2024, the Company owes management compensation of $270,000 and $180,000, respectively.

During the nine months ended August 31, 2025, and 2024, in connection with a month-to-month lease agreement with a company controlled by a related party, the Company recognized office rent expenses of $4,500 and $4,500, respectively. As of August 31, 2025, and November 30, 2024, the accounts payable and accrued liabilities consist of a payable rent of $6,000 and $1,500, respectively.

During the nine months ended August 31, 2025 and 2024, the Company issued 20,000 shares to one advisory board member and 430,000 shares of common stock to five advisory board members. The Company valued 20,000 shares based on recent stock subscriptions in cash at $1.00 per share ($20,000) and 430,000 shares based on the Company's control block stock offered at $0.00261 per share ($1,124) and recognized as compensation.

During the nine months ended August 31, 2024, the Company issued 2,650,000 shares of common stock to the Company's CEO and director and four board of directors' members, the shares were valued and recognized compensation of $6,735.

During the nine months ended August 31, 2024, the Company's board of directors approved the issuance of 100,000 shares of common stock for settlement of $50,000 management fees payable to the Company's CEO and director. The shares were valued at $262, resulting in a gain of settlement on debt of $49,738.

During the nine months ended August 31, 2024, the Company's board of directors approved the issuance of 102,200 shares of common stock for settlement of $48,639 due to AMJ Global Entertainment, LLC, a related party controlled by the Company's CEO. The shares were valued at $268, resulting in a gain of settlement on debt of $48,371.

As of August 31, 2025, and November 30, 2024, the Company owed $39,114 and $16,166, respectively to AMJ Global Entertainment LLC, a related party controlled by the Company's CEO and director The amount is unsecured, non-interest bearing and due on demand.

***Acquisition agreements:***

On July 13, 2024, the Company acquired 5% equity and revenue sharing agreement from a related party company in exchange for 133,334 shares of common stock, valued at $337. For the nine months ended August 31, 2025 and 2024, the Company recognized net revenue sharing of $133 and $8, respectively. As of August 31, 2025, the Company revalued the 5% Medicare contract asset and recognized impairment loss of $337 (see Note 3).

On January 24, 2025, the Company acquired from AMJ Global Entertainment LLC, a related party, its 25% equity interest in another company controlled by a related party, for amount of $1,000,000 in cash with payment term of two years with an extension of four months to pay the unpaid balance. In March 2026, the Company entered into a cancellation / unwinding agreement with AMJ Global Entertainment LLC.to cancel and terminate the original agreement and resolve any and all claims, obligations and liabilities arising there from with effective date of August 31, 2025. The Company acknowledges that agreement was determined not to have enforceable rights and obligations and hence the amounts related to the contract asset and corresponding loan payable, therefore the amounts related to the Medicare contract asset and corresponding loan payable would be rescinded and reversed on execution date of agreement (March 2026). For the nine months ended August 31, 2025, the Company recognized net revenue sharing of $531. As of August 31, 2025, the Company revalued the 25% Medicare contract asset and recognized impairment loss of $885,895 (see Note 3).

---

| |
|:---|
| F-11 |
| *[**Table of Contents**](#tocf)* |

---

As of August 31, 2025, the Company owed $1,000,000 to AMJ Global Entertainment LLC, a related party controlled by the Company's CEO and director with payment term of twenty-eight (28) months from the loan agreement date of January 24, 2025 (see Note 3 above). The amount is secured with restricted 1,000,000 shares of common stock. The Company recognized discount on non-interest-bearing loan issued by using Applicable Federal Rate (AFR) of 5.20% of $114,105 on acquisition date. In March, 2026, the Company entered into a cancellation / unwinding agreement with AMJ Global Entertainment LLC. to cancel and terminate the original agreement and resolve any and all claims, obligations and liabilities arising there from with effective date of August 31, 2025. The Company acknowledges that agreement was determined not to have enforceable rights and obligations and hence the amounts related to the contract asset and corresponding loan payable, therefore the amounts related to the Medicare contract asset and corresponding loan payable of $1,000,000 would be rescinded and reversed on execution date of agreement (March 2026).

**NOTE 6 – COMMON STOCK**

*Common Stock*

The Company has authorized common shares of 750,000,000, par value $0.001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

During the nine months ended August 31, 2024, the Company issued following shares:

---

| |
|:---|
| 2,000,000 shares of common stock to the Company's CEO and director, valued at $5,056. |
| 650,000 shares of common stock to the Company's board of directors, valued at $1,679. |
| 430,000 shares of common stock to the Company's advisory board members, valued at $1,124. |
| 100,000 shares of common stock against management fees payable to the Company's CEO and director, valued at $262. |
| 102,200 shares of common stock against amounts owed to AMJ Global Entertainment LLC, a related party controlled by the Company's CEO and director, valued at $268. |
| 133,334 shares of common stock issued for Medicare contracts asset, valued at $337 |
| 1,333,333 shares of common stock issued for software and development acquisition, valued at $3,371 |

---

During the nine months ended August 31, 2025, the Company issued and cancelled following shares:

---

| |
|:---|
| 6,000 shares of common stock issued for contribution of $6,000 in cash. |
| 20,000 shares of common stock issued to the Company's advisory board member, valued at $20,000. |
| 1,333,333 shares of common stock cancelled for unwinding and termination software and technology asset agreement, valued at $3,371 (see Note 4 above). |
| 2,000 shares of common stock were cancelled based on stockholder request, valued at $2. |

---

There were 106,472,857 and 107,782,190 shares of common stock issued and outstanding as of August 31, 2025, and November 30, 2024, respectively.

**NOTE 7 – COMMITMENTS AND CONTINGENCIES**

On January 27, 2025, the Company entered into a share exchange agreement with an entity for selling 5,000,000 shares of common restricted stock for $1.00 per share with 2,000,000 shares of common stock of Diamond Lake Mineral, Inc., a public company under laws of the state of Utah for $2.50 per share. On May 7, 2025, both parties agreed to unwind and terminate the original agreement dated January 27, 2025.

---

| |
|:---|
| F-12 |
| *[**Table of Contents**](#tocf)* |

---

**NOTE 8 – SUBSEQUENT EVENTS**

The Company has evaluated events occurring subsequent to the balance sheet date through the date these unaudited condensed financial statements were issued and determined there are no additional events requiring disclosure, except as follows:

On October 9, 2025, the Company issued 5,000,000 shares of restricted common stock to the Company's CEO and director and 450,000 shares of restricted common stock to three the Company's board members as compensation for services rendered to the Company.

In March 2026, the Company entered into a cancellation / unwinding agreement with AMJ Global Entertainment LLC.to cancel and terminate the original agreement and resolve any and all claims, obligations and liabilities arising there from with effective date of August 31, 2025 (see Note 3 above). The Company acknowledges that agreement was determined not to have enforceable rights and obligations and hence the amounts related to the contract asset and corresponding loan payable, therefore the amounts related to the Medicare contract asset and corresponding loan payable would be rescinded and reversed on execution date of agreement (March 2026).

---

| |
|:---|
| F-13 |
| *[**Table of Contents**](#toc)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Rule 175 under the Securities Act of 1933, and Rule 3b-6 under the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes," "seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q. Investors should carefully consider all of such risks before making an investment decision with respect to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements and summary of selected financial data for AMJ Global Technology. Such a discussion represents only the best present assessment from our Management.

**Description of Company**

AMJ Global Technology (the "Company") was incorporated under the laws of the State of Nevada on August 16, 2013, originally as "Kange Corp." Effective April 22, 2023, the Company filed with the State of Nevada a Certificate of Amendment to its Articles of Incorporation, changing the name of the Company to "AMJ Global Technology."

We previously focused on developing mobile software. During 2017, we began focusing on the intersection of technology and holistic technology-based health treatments. We retained an advisor having substantial experience in the technology sector, and two former professional athletes to advise us regarding sports health issues and treatments. We focused on formulating a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer's.

On April 26, 2023, the Company entered into an assignment agreement with AMJ Global Entertainment, LLC, a Nevada limited liability company controlled by the Company's CEO and director, pursuant to which AMJ Global Entertainment assigned to the Company 25% of the ownership rights to AMJ Global Entertainment's intellectual property in connection with the "Blabeey" platform, including software, code and trade secrets at zero cost.

In August of 2024, the Company entered into a Software Purchase and Development Agreement with Dataark Systems LLC, a Texas LLC ("Dataark"), pursuant to which the Company acquired an 8% interest in Dataark's ElephantSqlDB® database software in consideration of the issuance of 1,333,333 shares of Company common stock to Dataark. The ElephantSqlDB® database software is designed to leverage AI and quantum computing performance through a specialized architecture and algorithm called the Grover's Algorithm. The ElephantSqlDB® database is differentiated from its competitors in that is a single database that performs multiple database functions such as supporting 11 SQL dialects in addition to artificial intelligence (AI) data storage, SQL and NoSQL queries. The objective of this technology is to target and cut cloud infrastructure costs significantly while providing immutable security in order to combat evolving threats such as ransomware attacks. On May 7, 2025, the Company entered into an unwinding agreement with the owner of software and technology assets to terminate the agreement dated August 25, 2024. Upon the termination of the original agreement, neither party shall have any further obligations or liabilities under the original agreement, except as expressly provided in the unwinding agreement. The Company received 1,333,333 shares of common stock for cancellation on or about May 7, 2025, which shares were transferred back to the Company and were cancelled.

On July 13, 2024, the Company entered into a entered into a Revenue Sharing Agreement with Dark Bull Capital, Inc., a Nevada corporation ("Dark Bull") and related party controlled by a shareholder and Board member of the Company, Vern Barkdull, pursuant to which the Company would issue 133,334 shares of Company common stock to Dark Bull, and the Company will receive 5% of net revenue generated by Dark Bull from Dark Bull's contracts with (i) ESS in connection with Medicare enrollees, and (ii) The Agency of North Georgia in connection with Medicare, life and annuity insurance sales. The Company issued 133,334 shares of common stock issued on July 10, 2024, valued at $337.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#toc)* |

---

On January 24, 2025, the Company entered into a purchase agreement with AMJ Global Entertainment, LLC (the "Seller"), an entity controlled by the Company's CEO and director, Dr. Malone, for the acquisition of the Seller's 25% equity stake in Dark Bull for $1,000,000 in cash, with a payment term of two years and with an extension of four months to pay the unpaid balance. Should the Company not be able to pay the outstanding balance at the end of twenty-eight (28) months, the Seller has agreed to be paid any outstanding unpaid balance in the form of restricted common stock of the Company at the price of the Company's common stock at the time of signing agreement, which was $1.00 per share. In March 2026, the Company entered into a cancellation / unwinding agreement with Seller to cancel and terminate the original agreement and resolve any and all claims, obligations and liabilities arising there from with effective date of August 31, 2025. The Company acknowledge that agreement was determined not to have enforceable rights and obligations and hence the amounts related to the contract asset and corresponding loan payable, therefore the amounts related to the Medicare contract asset and corresponding loan payable would be rescinded and reversed on execution date of agreement (March 2026).

On January 27, 2025, the Company entered into a Stock Purchase Agreement with JP Michael LLC, pursuant to which the Company would sell 5,000,000 shares of Company common stock to JP Michael LLC in consideration of 2,000,000 shares of common stock of Diamond Lake Minerals, Inc. On May 7, 2025, both parties agreed to unwind and terminate the original agreement dated January 27, 2025.

We have had limited operations and have been issued a "going concern" opinion by our auditor on our November 30, 2024, audited financial statements based upon our reliance on related party (AMJ Global Entertainment, controlled by the Company's CEO and director) advances and the sale of our common stock as the sole source of funds for our operations for the near future.

The following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q.

**Reports to Security Holders**

We intend to furnish our shareholders annual reports containing financial statements audited by our independent registered public accounting firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year. We voluntarily file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission in order to disclose relevant information regarding the Company. We may also file additional documents with the Commission if they become necessary in the course of our company's operations.

The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is <u>www.sec.gov.</u>

**Results of Operations**

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed financial statements and notes thereto for the period ended August 31, 2025, which are included herein.

Our operating results for the three and nine months ended August 31, 2025, and 2024, and the changes between those periods for the respective items are summarized as follows.

***For the Three Months Ended August 31, 2025, and 2024***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | |
|  | **August 31,** | **August 31,** | |
|  | **2025** | **2024** | <br>**Change**<br>**Amount** |
| Revenue - related party  | $232 | $8 | $224 |
| Operating expenses | 36493 | 50833 | (14340) |
| Other expense | 898013 | - | 898013 |
| Net loss | $934274 | $50825 | $883449 |

---

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#toc)* |

---

During the three months ended August 31, 2025, and 2024, the Company recognized $232 and $8 revenue in connection with 5% and 25% net revenue sharing agreements generated from Medicare contract assets with a company controlled by a related party, respectively.

The Company incurred a net loss of $934,274 during the three months ended August 31, 2025, compared to a net loss of $50,825 for the three months ended August 31, 2024. The increase in net loss was primarily due to an increase in other expenses of $898,013, offset by a reduction in operating expenses of $14,340 and an increase in revenue-related party of $224.

Operating expenses for the three months ended August 31, 2025, and 2024, were $36,493 and $50,833 respectively. For the three months ended August 31, 2025, and 2024, the operating expenses were primarily attributed to management compensation of $30,000 and $35,764, professional fees of $4,891 and $7,949, and general and administrative expenses of $1,602 and $7,120, respectively.

Other expenses for the three months ended August 31, 2025, and 2024, were $898,013 and $0, respectively. For the three months ended August 31, 2025, the other expenses consist of impairment loss of $886,232 in connection with revaluation of Medicare contract assets of 5% and 25% -related party (see Financial Statements, Note 3) and interest expenses of $11,781.

***For the Nine Months Ended August 31, 2025, and 2024***

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** | |
|  | **August 31,** | **August 31,** | <br>**Change** |
|  | **2025** | **2024** | **Amount** |
| Revenue - related party | $674 | $8 | $666 |
| Operating expenses | 154995 | 145601 | 9394 |
| Other expense (income)  | 914367 | (98109) | 1012476 |
| Net loss | $1068688 | $47484 | $1021204 |

---

During the nine months ended August 31, 2025, and 2024, the Company recognized $674 and $8 revenue in connection with 5% and 25 % net revenue sharing agreements generated from Medicare contract assets with a company controlled by a related party, respectively.

The Company incurred a net loss of $1,068,688 during the nine months ended August 31, 2025, compared to a net loss of $47,484 for the nine months ended August 31, 2024. The increase in net loss was primarily due to an increase in operating expenses of $9,394 and other expenses (income) of $1,012,476, offset by an increase in revenue-related party of $666.

Operating expenses for the nine months ended August 31, 2025, and 2024, were $154,995 and $145,601 respectively. For the nine months ended August 31, 2025, and 2024, the operating expenses were primarily attributed to management compensation of $110,000 and $97,859, professional fees of $39,968 and $37,622, and general and administrative expenses of $5,027 and $10,120, respectively.

Other expenses (income) for the nine months ended August 31, 2025, and 2024, were $914,367 and ($98,109) respectively. For the nine months ended August 31, 2025, the other expenses consist of impairment loss of $886,232 in connection with revaluation of Medicare contract assets of 5% and 25% -related party (see Financial Statements, Note 3) and interest expenses of $28,135. For the nine months ended August 31, 2024, the other income was $98,109 for a gain on settlement of debt -related party.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#toc)* |

---

***Balance Sheet Data***

---

| | | | |
|:---|:---|:---|:---|
|  | **August 31,**<br>**2025** | **November 30,**<br>**2024** | **Increase** <br>**(Decrease)** |
| Cash | $110 | $226 | $(116) |
| Total Assets | $1054 | $9253 | $(8199) |
| Total Liabilities | $1238788 | $200928 | $1037860 |
| Working capital (deficiency) | $(1237734) | $(195383) | $(1042351) |

---

*Liquidity and Capital Resources*

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

The Company is currently evaluating operations in the holistic health industry, revenue sharing generated from Medicare enrollees, life and annuity insurance sales. This operation will generate revenue and cashflow for the Company and cash advances from related party.

*Working Capital*

As of August 31, 2025, our current assets were $1,054, and our current liabilities were $1,238,788, which resulted in working capital deficiency of $1,237,734.

As of August 31, 2025, current assets were comprised of $110 in cash, $664 in accounts receivable -related party and $280 in prepaid expenses, compared to $226 in cash, $39 in accounts receivable -related party and $5,280 in prepaid expenses as of November 30, 2024. As of August 31, 2025, current liabilities were comprised of $15,645 in accounts payable and accrued liabilities, $270,000 in accrued management fees - related party, $39,114 in due to related party and $914,029 due to related party -Medicare contract asset acquisition, compared to $4,762 in accounts payable and accrued liabilities, $180,000 in accrued management fees - related party, and $16,166 in amounts due to a related party as of November 30, 2024.

The due to related party of $914,029 in connection with Medicare contract assets of 25% would be rescinded and reversed on execution dated of cancellation / unwinding agreement in March 2026 (see Financial Statements, Note 3).

Our increase in working capital deficiency is primarily due to an increase in amounts due to a related party, management fees accrual and a decrease in cash and prepaid expenses.

***Cash Flow Data***

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 31,** | **August 31,** |
|  | **2025** | **2024** |
| Cash used in operating activities | $(29064) | $(39573) |
| Cash provided by investing activities |  |  |
| Cash provided by financing activities | 28948 | 39802 |
| Net change in cash for the period | $(116) | $229 |

---

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#toc)* |

---

*Cash Flows from Operating Activities*

We did not generate positive cash flows from operating activities for the nine months ended August 31, 2025, and 2024.

For the nine months ended August 31, 2025, net cash flows used in operating activities were $29,064, consisting of a net loss of $1,068,688, increased by accounts receivable - related party of $625 and reduced by impairment loss of Medicare contract assets of $886,232, imputed interest of $28,134, accrued management fees - related party of $90,000, stock-based compensation-related party of $20,000, changes in operating assets and liabilities of $15,883.

For the nine months ended August 31, 2024, net cash flows used in operating activities was $39,573 consisting of a net income of $47,484, increased by accounts receivable -related party of $8, gain on settlement of debt – related party of $98,109 and reduced by stock-based compensation – related party of $7,859, accrued management fees -related party of $90,000, changes in operating assets and liabilities of $8,169.

*Cash Flows from Investing Activities*

For the nine months ended August 31, 2025, and 2024, no cashflows were provided by or used in investing activities.

*Cash Flows from Financing Activities*

We fund our operations with cash received from advances from officers and related parties and issuances of equity.

For the nine months ended August 31, 2025, and 2024, AMJ Global Entertainment LLC, a related party controlled by the Company's CEO and director, advanced to the Company $25,274 and $39,802, by paying for operating expenses on behalf of the Company and the Company repaid advances to related party of $2,326 and $0, respectively.

During the nine months ended August 31, 2025, the Company received $6,000 for issuance of 6,000 shares of common restricted stock.

**Critical Accounting Policies**

*Use of Estimates.*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Going Concern**

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company used cash in operating activities of $29,064 for the nine months ended August 31, 2025. The Company had an accumulated deficit of $1,544,962 at August 31, 2025. These factors, among others, raise substantial doubts about the ability of the Company to continue as a going concern for a period of at least one year from date of issuance of the financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing, shareholder loans and to commence profitable operations in the future and repay its liabilities (due to related party-99% of total liabilities) arising from normal business operations as they become due. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for future periods. We have no assurance that future financing will be available to us on acceptable terms. Equity financing could result in additional dilation to existing shareholders.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#toc)* |

---

The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

**Off-Balance Sheet Arrangements**

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

As the Company is a "smaller reporting company," this item is inapplicable.

**ITEM 4. CONTROLS AND PROCEDURES.**

**Disclosure Controls and Procedures**

The Securities and Exchange Commission defines the term "disclosure controls and procedures" to mean the company's controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a simple system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC's rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. As of August 31, 2025, our disclosure controls and procedures were not effective due to (i) limited accounting personnel, resulting in insufficient segregation of duties, and (ii) lack of formalized period-end close and review controls. There were no changes in our Internal Control Over Financial Reporting ('ICFR") during the quarter that materially affected, or are reasonably likely to materially affect, our ICFR.

**Changes in Internal Control over Financial Reporting**

There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended August 31, 2025, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

On March 5, 2025, the Company notified Green Growth, CPA of its dismissal as the Company's independent registered public accounting firm. On March 5, 2025, the Company engaged Barton CPA PLLC of Cypress, Texas as the Company's independent registered public accounting firm.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#toc)* |

---

**PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS.**

The Company is not a party to any significant pending legal proceedings other than as disclosed below, and no other such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

**ITEM 1A. RISK FACTORS.**

Not applicable.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

The following issuances were made in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, based on the recipient's accredited investor status, no general solicitation, and investment intent. Securities were issued as restricted securities and bear the appropriate restrictive legends.

On March 18, 2025, the Company issued 6,000 shares of common stock to two third-party investors for $6,000 in cash.

On March 18, 2025, the Company issued 20,000 shares of common stock to advisory board member Jahmall Ellis for compensation valued at $20,000. Pursuant to his agreement with the Company, he was entitled to an equity aware of 20,000 shares on the one-year anniversary of the agreement.

On March 18, 2025, a stockholder returned and cancelled 2,000 shares of common stock that had been gifted to the stockholder by another stockholder.

On May 8, 2025, 1,333,333 shares of common stock were returned to the Company and cancelled pursuant to the termination of the Software Purchase and Development Agreement with Dataark described above, valued at $3,371.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES.**

None.

**ITEM 4. MINE SAFETY DISCLOSURES.**

None.

**ITEM 5. OTHER INFORMATION.**

None.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#toc)* |

---

**ITEM 6. EXHIBITS.**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [3.1](http://www.sec.gov/Archives/edgar/data/1593773/000159377314000002/kangearticles.htm) | [Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1, filed on February 21, 2014)](http://www.sec.gov/Archives/edgar/data/1593773/000159377314000002/kangearticles.htm) |
| [3.2](http://www.sec.gov/Archives/edgar/data/1593773/000159377314000002/kangecorpbylaws.htm) | [Bylaws (incorporated by reference to our Registration Statement on Form S-1, filed on February 21, 2014)](http://www.sec.gov/Archives/edgar/data/1593773/000159377314000002/kangecorpbylaws.htm) |
| [10.1](http://www.sec.gov/Archives/edgar/data/1593773/000147793215006869/kngr_ex991.htm) | [Assignment of Rights Agreement between the Company and AMJ Global (incorporated by reference to our Current Report on Form 8-K filed on November 12, 2015)](http://www.sec.gov/Archives/edgar/data/1593773/000147793215006869/kngr_ex991.htm) |
| [10.2](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex101.htm) | [Board Member Agreement, by and between the Company and Robert Stutman, dated March 26, 2024 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 1, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex101.htm) |
| [10.3](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex102.htm) | [Board Member Agreement, by and between the Company and Adrian Neilan, dated March 26, 2024 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on April 1, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex102.htm) |
| [10.4](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex103.htm) | [Board Member Agreement, by and between the Company and Jesse Anglen, dated March 26, 2024 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed on April 1, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex103.htm) |
| [10.5](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex104.htm) | [Board Member Agreement, by and between the Company and Vern Barkdull, dated March 26, 2024 (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed on April 1, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224001636/kgnr_ex104.htm) |
| [10.6](http://www.sec.gov/Archives/edgar/data/1593773/000147793224004273/kgnr_ex101.htm) | [Revenue Sharing Agreement, by and between the Company and Dark Bull, dated July 13, 2024 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on July 18, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224004273/kgnr_ex101.htm) |
| [10.7](http://www.sec.gov/Archives/edgar/data/1593773/000147793224005307/kgnr_ex101.htm) | [Software Purchase and Development Agreement between AMJ Global Technology and Dataark Systems LLC, dated August 25, 2024 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 27, 2024)](http://www.sec.gov/Archives/edgar/data/1593773/000147793224005307/kgnr_ex101.htm) |
| [10.8](http://www.sec.gov/Archives/edgar/data/1593773/000147793225000457/kgnr_ex101.htm) | [Purchase Agreement, by and between the Company and AMJ Global Entertainment LLC, dated January 24, 2025 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 27, 2025)](http://www.sec.gov/Archives/edgar/data/1593773/000147793225000457/kgnr_ex101.htm) |
| [10.9](http://www.sec.gov/Archives/edgar/data/1593773/000147793225000485/kgnr_ex101.htm) | [Stock Purchase Agreement, by and between the Company and JP Michael LLC, dated January 27, 2025 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 28, 2025)](http://www.sec.gov/Archives/edgar/data/1593773/000147793225000485/kgnr_ex101.htm) |
| [10.10\*](amj_ex1010.htm) | [Cancelation Agreement, by and between the Company and AMJ Global Entertainment LLC, dated August 31, 2025 for cancellation original agreement dated January 27, 2025](amj_ex1010.htm) |
| [31.1/31.2\*](amj_ex311.htm) | [Certification of Chief Executive Officer and Chief Executive Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](amj_ex311.htm) |
| [32.1/32.2\*](amj_ex321.htm) | [Certification of Chief Executive Officer and Chief Executive Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63](amj_ex321.htm) |
| 101\* | Inline XBRL Document Set for the condensed financial statements and accompanying notes in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q. |
| 104\* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |

---

____________

\* Filed herewith.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#toc)* |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AMJ Global Technology** | **AMJ Global Technology** |
| Date: May 7, 2026 | By: | */s/ Dr. Arthur Malone, Jr.* |
|  |  | Dr. Arthur Malone, Jr. |
|  |  | Chief Executive Officer,<br>Chief Financial Officer and Director |

---

## Exhibit 10.10

**EXHIBIT 10.10**

---

| | |
|:---|:---|
| By: | */s/ Dr. Art Malone Jr* |
| Name: | Dr. Art Malone Jr |
| Title: | Chairman/CEO/Secretary |
| 8/31/2025 | 8/31/2025 |

---

---

| | |
|:---|:---|
| **AMJ GLOBAL ENTERTAINMENT LLC** | **AMJ GLOBAL ENTERTAINMENT LLC** |
| By: | */s/ Dr. Art Malone Jr* |
| Name: | Dr. Art Malone Jr |
| Title: | Managing Director |
| 8/31/2025 | 8/31/2025 |

---

![](amj_ex1010img4.jpg)

![](amj_ex1010img5.jpg)

## Exhibit 31.1

**EXHIBIT 31.1 /31.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**AND PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT AND RULE 13A-14(A)**

**OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934**

I, Dr. Arthur Malone Jr., certify that:

1. I have reviewed this report on Form 10-Q of AMJ Global Technology, for the quarter ended August 31, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 7, 2026 | By: | */s/ Dr. Arthur Malone, Jr.* |
|  |  | Dr. Arthur Malone, Jr. |
|  |  | Chief Executive Officer,<br> Chief Financial Officer and Director |

---

## Exhibit 32.1

**EXHIBIT 32.1 /32.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**AND PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER** 

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of AMJ Global Technology (the "Company"), for the quarter ended August 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dr. Arthur Malone, Jr., Chief Executive Officer, Chief Financial Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

| | | |
|:---|:---|:---|
| Date: May 7, 2026 | By: | */s/ Dr. Arthur Malone, Jr.* |
|  |  | Dr. Arthur Malone, Jr.<br> Chief Executive Officer |
|  |  | Chief Financial Officer and Director |

---